Opus Genetics, Inc.
IRDHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeOpus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of. Valued at $270.0M, IRD is a micro-cap name in its sector. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
Market Cap
$270.0M
Beta
0.56
P/E (TTM)
—
P/E (Fwd)
-4.28
EPS (TTM)
$-1.30
EPS (Fwd)
$-0.76
ROE
-7594.6%
ROA
-46.8%
Cash
$60.0M
Total Debt
$1.2M
Free CF
-$39.3M
52W Change
189.4%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $60.0M in cash comfortably exceeding the $1.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$39.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -7594.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $39.9M (2022) to $14.2M (2025), a 64% decline worth watching.
With a beta below 0.7, Opus Genetics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Opus Genetics, Inc.'s trajectory.